Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00452530
First received: March 23, 2007
Last updated: February 28, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots.

The safety of apixaban will also be studied.


Condition Intervention Phase
Deep Vein Thrombosis
Pulmonary Embolism
Drug: Enoxaparin + Placebo
Drug: Apixaban + Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • A combination of adjudicated asymptomatic and symptomatic DVT, non-fatal PE and all-cause death [ Time Frame: after 12 days of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • A combination of adjudicated asymptomatic and symptomatic proximal DVT, non-fatal PE, & VTE-related death [ Time Frame: after 12 days of treatment ] [ Designated as safety issue: No ]

Enrollment: 3054
Study Start Date: June 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A1
+ placebo
Drug: Enoxaparin + Placebo
Syringes + tablets, Subcutaneous + Oral, 40 mg, once daily, 12 days
Other Name: Lovenox®
Experimental: A2
+ placebo
Drug: Apixaban + Placebo
Tablet + Syringes, Oral + subcutaneous, 2.5mg, twice daily, 12 days
Other Name: BMS-562247

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • men and non-pregnant, non-breastfeeding women
  • 18 years or older
  • scheduled for total knee replacement surgery

Exclusion Criteria:

  • hereditary or acquired bleeding disorders
  • clotting disorders
  • bleeding or high risk for bleeding
  • drugs that affect bleeding or coagulation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00452530

  Hide Study Locations
Locations
Austria
Local Institution
Graz, Austria, 8036
Local Institution
Innsbruck, Austria, 6020
Local Institution
Linz, Austria, 4010
Local Institution
Wels, Austria, 4600
Local Institution
Wien, Austria, 1090
Local Institution
Wien, Austria, 1130
Local Institution
Wiener Neustadt, Austria, 2700
Belgium
Local Institution
Antwerpen, Belgium, 2020
Local Institution
Hasselt, Belgium, 3500
Brazil
Local Institution
Belo Horizonte - Mg, Minas Gerais, Brazil, 30130
Local Institution
Sao Paulo, Brazil, 04023
Chile
Local Institution
Santiago, Metropolitana, Chile, 7500922
Local Institution
Santiago, Metropolitana, Chile, 8330033
China, Beijing
Local Institution
Beijing, Beijing, China, 100035
Local Institution
Beijing, Beijing, China, 100835
China, Shandong
Local Institution
Qingdao, Shandong, China, 266003
China, Shanghai
Local Institution
Shanghai, Shanghai, China, 200025
Local Institution
Shanghai, Shanghai, China, 200233
Local Institution
Shanghai, Shanghai, China, 200011
Colombia
Local Institution
Bogota, Colombia
Local Institution
Bogota, Colombia, XXXXX
Local Institution
Cali, Colombia, - - - - -
Local Institution
Medelin, Colombia, -----
Czech Republic
Local Institution
Brno, Czech Republic, 662 50
Local Institution
Chomutov, Czech Republic, 430 12
Local Institution
Pardubice, Czech Republic, 532 03
Local Institution
Prague 8, Czech Republic, 180 81
Local Institution
Uherske Hradiste, Czech Republic, 686 68
Denmark
Local Institution
Hellerup, Denmark, 2900
Local Institution
Hvidovre, Denmark, 2650
Local Institution
Kolding, Denmark, 6000
Local Institution
Viborg, Denmark, 8800
France
Local Institution
Monaco, France, 98000
Local Institution
Nice, France, 06200
Local Institution
Paris, France, 75019
Local Institution
Paris, France, 75679
Local Institution
Paris, France, 75014
Local Institution
Saint-Saulve, France, 59880
Germany
Local Institution
Bad Mergentheim, Germany, 97980
Local Institution
Bochum, Germany, 44791
Local Institution
Brandenburg, Germany, 14770
Local Institution
Dresden, Germany, 01307
Local Institution
Frankfurt, Germany, 65929
Local Institution
Frankfurt Am Main, Germany, 60528
Local Institution
Halle/S, Germany, 06112
Local Institution
Kremmen Ot Sommerfeld, Germany, 16766
Local Institution
Rheinfelden, Germany, 79618
Local Institution
Witten, Germany, 58455
Hungary
Local Institution
Szeged, Hungary, 6725
Local Institution
Szekszard, Hungary, 7100
India
Local Institution
Ahmedabad, Gujarat, India, 380054
Local Institution
Ludhiana, Punjab, India, 141001
Local Institution
Bangalore, India, 560034
Local Institution
Baroda, India, 390007
Local Institution
Mangalore, India, 575001
Israel
Local Institution
Jeruselem, Israel, 91031
Local Institution
Petach-Tikva, Israel, 49372
Local Institution
Safed, Israel, 13110
Local Institution
Tel Aviv, Israel, 64239
Local Institution
Tel Hashomer, Israel, 52621
Italy
Local Institution
Abano Terme (Pd), Italy, 35031
Local Institution
Bologna, Italy, 40136
Local Institution
Pordenone, Italy, 33170
Local Institution
Roma, Italy, 00168
Local Institution
San Donato Milanese (Mi), Italy, 20097
Korea, Republic of
Local Institution
Jeonnam, Korea, Republic of, 519-809
Local Institution
Seoul, Korea, Republic of, 110-744
Local Institution
Seoul, Korea, Republic of, 138-736
Local Institution
Seoul, Korea, Republic of, 136-705
Malaysia
Local Institution
Kuala Lumpur, Malaysia, 56000
Local Institution
Kuala Lumpur, Malaysia, 50586
Mexico
Local Institution
Zapopan, Jalisco, Mexico, 45200
Local Institution
Hermosillo, Sonora, Mexico, 83190
Local Institution
Aguascalientes, Mexico, 20010
Local Institution
San Luis Potosi, Mexico, 78340
Local Institution
Veracruz, Mexico, 91700
Norway
Local Institution
Alesund, Norway, 6026
Local Institution
Gjettum, Norway, 1346
Local Institution
Kongsvinger, Norway, 2212
Philippines
Local Institution
Manila, Philippines, 1000
Local Institution
Quezon City, Philippines, 1114
Local Institution
Quezon City, Philippines, 1102
Poland
Local Institution
Bytom, Poland, 41-902
Local Institution
Gdansk, Poland, 80-803
Local Institution
Warszawa, Poland, 03-242
Local Institution
Wroclaw, Poland, 50-556
Russian Federation
Local Institution
Chelyabinsk, Russian Federation, 454021
Local Institution
Kazan, Russian Federation, 420029
Local Institution
Lipetsk, Russian Federation, 398035
Local Institution
Moscow, Russian Federation, 115522
Local Institution
Rostov-Na-Donu, Russian Federation, 344010
Local Institution
Saint Petersburg, Russian Federation, 199106
Local Institution
Saint Petersburg, Russian Federation, 194354
Local Institution
Saint Petersburg, Russian Federation, 195427
Local Institution
Saint Petersburg, Russian Federation, 193312
Local Institution
Samara, Russian Federation, 443095
Singapore
Local Institution
Singapore, Singapore, 169608
Local Institution
Singapore, Singapore, 529889
South Africa
Local Institution
Randburg, Free State, South Africa, 2194
Local Institution
Johannesburg, Gauteng, South Africa, 2193
Local Institution
Johannesburg, Gauteng, South Africa, 2031
Local Institution
Pretoria, Gauteng, South Africa, 0083
Local Institution
Somerset West, Western Cape, South Africa, 7130
Local Institution
Tygerberg, Western Cape, South Africa, 7505
Local Institution
Worcester, Western Cape, South Africa, 6850
Spain
Local Institution
Badalona-Barcelona, Spain, 08916
Local Institution
Barcelona, Spain, 08035
Local Institution
Barcelona, Spain, 08006
Local Institution
Barcelona, Spain, 08024
Local Institution
Madrid, Spain, 28034
Local Institution
Santiago De Compostela, Spain, 15706
Local Institution
Valencia, Spain, 46010
Sweden
Local Institution
Boras, Sweden, 501 82
Ukraine
Local Institution
Cherkassy, Ukraine, 18009
Local Institution
Chernivtsy, Ukraine, 58013
Local Institution
Dnipropetrovsk, Ukraine, 49005
Local Institution
Ivano-Frankivsk, Ukraine, 76008
Local Institution
Kyiv, Ukraine, 01601
Local Institution
Kyiv, Ukraine, 04107
Local Institution
Sevastopol, Ukraine, 99018
United Kingdom
Local Institution
London, Greater London, United Kingdom, SE5 9PJ
Local Institution
Epsom, Surrey, United Kingdom, KT18 7EG
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00452530     History of Changes
Other Study ID Numbers: CV185-047, EUdraCT: 2006-006896-19
Study First Received: March 23, 2007
Last Updated: February 28, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Thrombosis
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Enoxaparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on April 15, 2014